Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Ohio Med Spas: Peptide Do's and Do Not's

Client Alert
April 29, 2026

Recent Ohio Board of Pharmacy (“BOP”) guidance has highlighted compliance considerations surrounding the use of peptides in med spas.  Owners and operators of med spas will want to keep these considerations in mind as the use of peptides, especially GLP-1 medications, expands.  

Certain peptide drugs are FDA approved medications and can be used in med spas. However, not every peptide-based drug is created equal or is approval by the FDA. According to BOP guidance, some peptides, such as Retatrutide, are not currently FDA approved.[1] In addition, many peptide-based drugs, such as Semaglutide or BPC-157 peptides, cannot currently be compounded.[2]

The BOP conducts regular inspections of med spas and has revoked or suspended several med-spa’s TDDD licenses for violations surrounding the use of peptides. The most common violations are purchasing medication from an unlicensed seller, purchasing and utilizing medication marked “for research purposes only,” purchasing non-FDA approved medication, and obtaining foreign sourced medication.   

When determining which peptides your med-spa can utilize, it is important to keep the following considerations in mind:

  • Only use peptides that are FDA approved.
  • Do not purchase peptides from unlicensed sellers.
  • Do not use peptides labeled “for research purposes only.”
  • Ensure compliance with compounding requirements, including not making prohibited copies of peptides.
  • Properly store any peptides prior to their use.

If you have questions regarding BOP compliance or how using peptides may impact your practice, please contact BMD Member Jeana Singleton at jmsingleton@bmdllc.com or 330-253-2001.     

[1] Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio, Ohio Board of Pharmacy, last accessed April 23, 2026.

[1] Ten Common Prescriber Clinic and Medical Spa Violations, Ohio Board of Pharmacy, last accessed April 23, 2026. See also, Compounding of Glucagon-like Peptide-1 Drug Products (GLP-1) in Ohio, Ohio Board of Pharmacy, last accessed April 23, 2026.

HealthcareHealth LawOhio State Board of PharmacyMedSpaJeana Singleton
Client Alert

Understanding the Seven Core Elements of an Effective Healthcare Compliance Program

January 22, 2026The Affordable Care Act requires healthcare providers participating in Medicare, Medicaid, and CHIP to maintain an effective compliance program. Guidance from the Department of Health and Human Services and the Office of Inspector General outlines seven core elements that form the foundation of these programs, from written policies and compliance oversight to auditing, training, and corrective action. This alert highlights each element and explains how practices can tailor compliance programs to their size and risk profile while meeting federal expectations.Client Alert

Preventing a Board Investigation

January 21, 2026Healthcare professionals in Ohio are subject to licensing board investigations that can lead to disciplinary action. Staying compliant with regulations, documenting carefully, and operating within your professional scope can help prevent issues. If contacted by a board, working with an attorney is critical to protect your license and rights.Client Alert

Ohio Board of Nursing Proposes Rule Changes for Nurses

January 14, 2026On Monday, January 12, 2026, the Ohio Board of Nursing (“BON”) released a package of proposed changes to the Ohio Administrative Code. There are two proposed changes to continuing education requirements that Ohio nurses should be watching.Client Alert

New Florida Law: Patient Overpayments Must Be Refunded Within 30 Days

December 22, 2025Effective January 1, 2026, Florida Senate Bill 1808 requires health care facilities and practitioners to refund patient overpayments within 30 days after an overpayment is identified. The law applies to overpayments tied to claims submitted to government programs or private insurers and introduces fines and disciplinary consequences for noncompliance. Providers should review billing and payment practices now to prepare for the new requirements.Client Alert

USCIS Policy Change Impacting Work Authorization: Advisory for Employers and Human Resources

December 8, 2025USCIS has issued a policy memorandum pausing immigration benefit processing for individuals from 19 high-risk countries and requiring a re-review of certain previously approved cases. This change may affect work authorization, employment verification, and workforce stability. Employers and HR teams should review impacted employees and update compliance procedures.
Older posts
Newer posts